Lifecore Biomedical, Inc.

As of January 2, 2025, Lifecore Biomedical, Inc. is considered overvalued with a risky valuation grade, reflected by a high Price to Book Value of 5.35, negative EV to EBIT and EV to EBITDA ratios, and poor ROCE and ROE metrics, despite a strong 1-year stock return of 52.50%.

As of January 2, 2025, Lifecore Biomedical, Inc. is considered overvalued and risky due to poor performance indicators, including a Price to Book Value of 5.35 and an ROE of -89.08%, which are significantly worse than its peers, despite a recent 1-year stock return of 47.21%.

As of March 2022, the management team of Lifecore Biomedical, Inc. includes Independent Chairman Mr. Craig Barbarosh, President and CEO Dr. Albert Bolles, and Directors Mr. Jeffrey Edwards, Mr. Joshua Schechter, Mr. Patrick Walsh, Independent Director Ms. Deborah Carosella, and Independent Director Ms. Katrina Houde. They oversee the company's operations and strategic direction.

Lifecore Biomedical, Inc. designs and manufactures health and wellness products in the Pharmaceuticals & Biotechnology sector, with recent net sales of $35 million and a net loss of $15 million. The company has a market cap of $252.14 million and operates in the micro-cap market.

As of Jun 18, Lifecore Biomedical, Inc. has a market capitalization of 252.14 million, with net sales of 130.30 million and a net profit of -44.66 million over the last four quarters. The company reported shareholder's funds of 53.90 million and total assets of 273.70 million as of May 24.